文献速递乳腺癌支持与姑息治疗

POSITIVE试验更新结果:内分泌治疗暂停妊娠安全性

Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial.
PubMed 文献 · Ann Oncol · 2026-05-28

POSITIVE单臂前瞻性试验纳入518例≤42岁、I-III期HR阳性早期乳腺癌且希望妊娠的患者,评估辅助内分泌治疗暂停最多2年的安全性。中位随访71个月,5年BCFI事件累积发生率12.3%,与外对照SOFT/TEXT的13.2%相比差异为-0.9%(95%CI -4.2%至2.6%);76%患者至少一次妊娠,69%至少一次活产。

要点

  • 辅助内分泌治疗暂停妊娠未增加乳腺癌事件风险。
  • 5年BCFI事件率12.3%,与外部对照差异-0.9%。
  • 76%患者试验期间至少一次妊娠,69%活产。

核心结论

  • POSITIVE试验更新随访显示,为妊娠暂时中断内分泌治疗包括使用生育力保存不增加乳腺癌事件风险。
  • 鉴于该人群已知的晚期复发风险,仍需继续随访。

研究设计与样本

  • POSITIVE为单臂前瞻性试验,评估辅助内分泌治疗(18-30个月后开始,最多2年)暂停以尝试妊娠。
  • 2014年12月至2019年12月共纳入518例合格女性(≤42岁、I-III期乳腺癌、希望妊娠)。
  • 采用bootstrap匹配方法与SOFT/TEXT试验作为外部对照比较5年BCFI和DRFI事件率。

主要发现

  • POSITIVE队列中位随访71个月,SOFT/TEXT队列中位随访80个月。
  • 5年BCFI事件累积发生率在POSITIVE为12.3%,在SOFT/TEXT为13.2%,差异-0.9%(95%CI -4.2%至2.6%)。
  • 5年DRFI事件累积发生率分别为6.2%和8.3%,差异-2.1%(95%CI -4.5%至0.4%)。
  • 497例随访非疾病结局的女性中,377例(76%)在试验期间至少一次记录妊娠,343例(69%)至少一次活产,共440名后代。
  • 未调整分析中,180例(36%)入组前进行胚胎/卵母细胞冷冻保存者与未保存者5年BCFI事件累积发生率分别为14.0%(95%CI 9.6%至20.2%)和11.5%(95%CI 8.4%至15.7%)。

临床怎么用

  • 对HR阳性早期乳腺癌年轻患者,在充分知情后可按试验方案考虑暂时中断内分泌治疗以尝试妊娠。
  • 生育力保存的使用未显示增加乳腺癌事件风险,可作为妊娠计划的一部分讨论。

局限性

  • 单臂设计,与外部对照比较可能存在混杂。
  • 随访时间仍不足以完全评估晚期复发风险,需继续随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with hormone receptor (HR)-positive early breast cancer (BC), the POSITIVE trial demonstrated that temporary interruption of adjuvant endocrine therapy (ET) for pregnancy is feasible and safe in early follow-up (median 41 months). In this article, we report updated results from a preplanned analysis with 2.5 years of additional follow-up. PATIENTS AND METHODS: POSITIVE, a single-arm prospective trial evaluating temporary interruption of adjuvant ET (after 18-30 months and for up to 2 years) to attempt pregnancy in young patients with BC, enrolled 518 eligible women (≤42 years of age, stage I-III BC, desiring pregnancy) from December 2014 to December 2019. Using the bootstrap-matching method, 5-year breast cancer-free interval (BCFI) and distant recurrence-free interval (DRFI) event rates were compared with those of the SOFT/TEXT trials as external controls. RESULTS: At a median follow-up of 71 months in the POSITIVE cohort and 80 months in the SOFT/TEXT cohort, the 5-year cumulative incidence of BCFI events was 12.3% in POSITIVE and 13.2% in SOFT/TEXT [-0.9% difference, 95% confidence interval (CI) -4.2% to 2.6%]. The 5-year cumulative incidence of DRFI events was 6.2% and 8.3%, respectively (-2.1% difference, 95% CI -4.5% to 0.4%). Among 497 women followed for nondisease outcomes, 377 (76%) had ≥1 documented pregnancy on trial, and 343 of 497 (69%) had ≥1 live birth, totaling 440 offspring. In an unadjusted analysis comparing the 180 women (36%) who had pre-enrollment embryo/oocyte cryopreservation with those who did not, the 5-year cumulative incidence of BCFI events was 14.0% (95% CI 9.6% to 20.2%) and 11.5% (95% CI 8.4% to 15.7%), respectively. CONCLUSION: Longer-term follow-up of the POSITIVE trial demonstrates that temporary interruption of ET for pregnancy, including use of fertility preservation, does not increase the risk of BC events. Continued follow-up is warranted given the known risk of late recurrence in this population.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Pagani O, Niman SM, Ruggeri M, et al. Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial. Ann Oncol. 2026. PMID: 42214557. doi:10.1016/j.annonc.2026.05.699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。